Search results for "Array"

showing 10 items of 1264 documents

The humoral immune system has a key prognostic impact in node-negative breast cancer.

2008

Abstract Estrogen receptor (ER) expression and proliferative activity are established prognostic factors in breast cancer. In a search for additional prognostic motifs, we analyzed the gene expression patterns of 200 tumors of patients who were not treated by systemic therapy after surgery using a discovery approach. After performing hierarchical cluster analysis, we identified coregulated genes related to the biological process of proliferation, steroid hormone receptor expression, as well as B-cell and T-cell infiltration. We calculated metagenes as a surrogate for all genes contained within a particular cluster and visualized the relative expression in relation to time to metastasis with…

OncologyAdultCancer Researchmedicine.medical_specialtyMultivariate analysisEstrogen receptorBreast NeoplasmsMetastasisCohort StudiesBreast cancerImmune systemInternal medicineMedicineCluster AnalysisHumansAgedCell ProliferationOligonucleotide Array Sequence AnalysisAged 80 and overbusiness.industryProportional hazards modelGene Expression ProfilingHazard ratioCarcinomaMiddle Agedmedicine.diseasePrognosisGene Expression Regulation NeoplasticOncologyNeutrophil InfiltrationLymphatic MetastasisCohortImmunologyAntibody FormationFemaleLymph NodesbusinessGenes NeoplasmCancer research
researchProduct

Prognostic impact of phosphorylated HER-2 in HER-2+ primary breast cancer.

2011

Abstract Purpose. Tyrosine 1248 is one of the autophosphorylation sites of human epidermal growth factor receptor (HER)-2. We determined the prognostic value of the expression level of tyrosine 1248–phosphorylated HER-2 (pHER-2) in patients with HER-2+ primary breast cancer using a reverse-phase protein array. Patients and Methods. The optimal cutoff value of pHER-2 for segregating disease-free survival (DFS) was determined by receiver operating characteristic (ROC) curve analysis. Five-year DFS for pHER-2 expression level was estimated with the Kaplan-Meier method using both derivation (n = 162) and validation (n = 227) cohorts. Results. Of the 162 patients in the derivation cohort, 26 had…

OncologyAdultCancer Researchmedicine.medical_specialtyPathologyReceptor ErbB-2Breast NeoplasmsMetastasesDisease-Free SurvivalBreast cancerBreast cancerReverse-phase protein arrayInternal medicineBreast CancermedicineHumansTyrosinePhosphorylationIn Situ Hybridization FluorescenceAgedAged 80 and overReceiver operating characteristicintegumentary systembusiness.industryAutophosphorylationReverse phase protein lysate microarrayMiddle Agedmedicine.diseasePrognosisImmunohistochemistryOncologyHER-2PhosphorylationImmunohistochemistryFemalePrimary breast cancerbusinessThe oncologist
researchProduct

Triple-negative breast cancer: Molecular features, pathogenesis, treatment and current lines of research

2010

Breast cancer is a heterogeneous disease with different morphologies, molecular profiles, clinical behaviour and response to therapy. The triple negative is a particular type of breast cancer defined by absence of oestrogen and progesterone receptor expression as well as absence of ERBB2 amplification. It is characterized by its biological aggressiveness, worse prognosis and lack of a therapeutic target in contrast with hormonal receptor positive and ERBB2+ breast cancers. Given these characteristics, triple-negative breast cancer is a challenge in today's clinical practice. A new breast cancer classification emerged recently in the scientific scene based in gene expression profiles. The ne…

OncologyCA15-3medicine.medical_specialtyMicroarrayReceptor ErbB-2business.industryCancerBreast NeoplasmsGeneral MedicineDiseasemedicine.diseaseBreast cancerReceptors EstrogenOncologyInternal medicinemedicineHumansFemaleRadiology Nuclear Medicine and imagingReceptors Progesteroneskin and connective tissue diseasesBreast cancer classificationbusinessTriple-negative breast cancerEGFR inhibitorsCancer Treatment Reviews
researchProduct

Serum microRNA profiles as prognostic/predictive markers in the multimodality therapy of locally advanced adenocarcinomas of the gastroesophageal jun…

2014

Neoadjuvant multimodality treatment is frequently applied to improve the poor prognosis of locally advanced adenocarcinomas of the gastroesophageal junction. This study aimed to asses if serum microRNA profiles are useable as response indicators in this therapeutic setting. Fifty patients with locally advanced adenocarcinomas of the gastroesophageal junction were included in the study. All patients received neoadjuvant therapy and subsequently underwent surgical resection. Histomorphologic regression was defined as major histopathological response when resected specimens contained less than 10% vital residual tumor cells. Circulating RNA was isolated from pretherapeutic/post-neoadjuvant blo…

OncologyCancer ResearchPathologymedicine.medical_specialtyMicroarraybusiness.industrymedicine.medical_treatmentRetrospective cohort studyMultimodality TherapyGene expression profilingBlood serumOncologyInternal medicinemicroRNAMedicinebusinessNeoadjuvant therapyChemoradiotherapyInternational Journal of Cancer
researchProduct

KRAS mutation signature in colorectal tumors significantly overlaps with the cetuximab response signature.

2008

OncologyCancer Researchmedicine.medical_specialtyCetuximabAntineoplastic AgentsAntibodies Monoclonal HumanizedProto-Oncogene Proteins p21(ras)Text miningInternal medicineProto-Oncogene ProteinsmedicineCluster AnalysisHumansColorectal TumorsNeoplasm StagingOligonucleotide Array Sequence AnalysisCetuximabbusiness.industryGene Expression ProfilingPatient SelectionAntibodies MonoclonalSignature (logic)ErbB ReceptorsGene Expression Regulation NeoplasticTreatment OutcomeOncologyMutationras ProteinsbusinessColorectal NeoplasmsKras mutationmedicine.drugJournal of clinical oncology : official journal of the American Society of Clinical Oncology
researchProduct

Prognostic significance of the chemokine CXCL13 in node-negative breast cancer

2013

615 Background: The chemokine CXCL13 is chemotactic for B cells. We examined the prognostic significance of CXCL13 mRNA expression in node-negative breast cancer. Methods: Microarray based gene-expression data for CXCL13 (205242_at) were analysed in four previously published cohorts (Mainz, Rotterdam, Transbig, Yu) of node-negative breast cancer patients not treated with adjuvant therapy (n=824). A meta-analysis of previously published cohorts was performed using a random effects model. Prognostic significance of CXCL13 on metastasis-free survival (MFS) was examined in the whole cohort and in different molecular subtypes (ER+/HER2-, ER-/HER2-, HER2+). Independent prognostic relevance was a…

OncologyCancer Researchmedicine.medical_specialtyChemokineMicroarraybiologybusiness.industryMrna expressionObstetrics and GynecologyChemotaxismedicine.diseaseNode negativeBreast cancerOncologyInternal medicineMaternity and MidwiferyImmunologyCancer researchbiology.proteinMedicineCXCL13businessGeburtshilfe und Frauenheilkunde
researchProduct

Single nucleotide polymorphism array karyotyping: A diagnostic and prognostic tool in myelodysplastic syndromes with unsuccessful conventional cytoge…

2013

Cytogenetic aberrations identified by metaphase cytogenetics (MC) have diagnostic, prognostic, and therapeutic implications in myelodysplastic syndromes (MDS). However, in some MDS patients MC study is unsuccesful. Single nucleotide polymorphism array (SNP-A) based karyotyping could be helpful in these cases. We performed SNP-A in 62 samples from bone marrow or peripheral blood of primary MDS with an unsuccessful MC study. SNP-A analysis enabled the detection of aberrations in 31 (50%) patients. We used the copy number alteration information to apply the International Prognostic Scoring System (IPSS) and we observed differences in survival between the low/intermediate-1 and intermediate-2/h…

OncologyCancer Researchmedicine.medical_specialtyMyelodysplastic syndromesSingle Nucleotide Polymorphism ArrayCytogeneticsKaryotypeBiologymedicine.diseaseGene dosagemedicine.anatomical_structurePolymorphism (computer science)International Prognostic Scoring SystemInternal medicineGeneticsmedicineBone marrowGenes, Chromosomes and Cancer
researchProduct

Abstract P2-05-04: Gene expression associated with poor prognosis of young TNBC patients

2015

Abstract Background: Among TNBC patients those of very young age (<40 years) display a significantly worse prognosis (Liedtke et al. 2013 Breast Cancer Res Treat). We verified this result in 1161 TNBC samples with full Affymetrix gene expression data of which 845 patients had both detailed age and follow up information. Materials and Methods: We split the full sample set into a finding cohort of 394 TNBC and a validation cohort of 767 TNBC encompassing 309 and 536 samples, respectively, with both age and follow up data. We then used significance analysis of microarrays (SAM) in the finding cohort to look for genes whose expression is associated with young age (<40 years). Iden…

OncologyCancer Researchmedicine.medical_specialtyPoor prognosisbusiness.industryCancermedicine.diseaseFull sampleYoung ageBreast cancerOncologyInternal medicineImmunologyGene expressionCohortSignificance analysis of microarraysmedicinebusinessCancer Research
researchProduct

Immunoglobulin Kappa C Has Independent Prognostic Significance in Node-Negative Breast Cancer.

2009

Abstract Background: Utilizing microarray based gene-expression analysis of fresh-frozen tissue we could recently demonstrate the prognostic impact of a B cell metagene in node-negative breast cancer (Cancer Res 68: 5405-5413, 2008). In the present study we investigated the prognostic significance of immunoglobulin kappa c (IGKC) in formalin-fixed paraffin embedded (FFPE) breast cancer specimens of 363 node-negative breast cancer patients which were not treated in the adjuvant setting.Methods: RT-PCR was used to analyze mRNA expression of IGKC in FFPE tissue of 363 patients with node-negative breast cancer. Additionally to IGKC we examined the prognostic impact of age, histological grade, t…

OncologyCancer Researchmedicine.medical_specialtyUnivariate analysisPathologyMicroarraybusiness.industrymedicine.medical_treatmentEstrogen receptorCancermedicine.diseaseBreast cancermedicine.anatomical_structureOncologyInternal medicineProgesterone receptormedicinebusinessAdjuvantB cellCancer Research
researchProduct

Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study.

2010

Summary Background Knowledge about the distribution of human papillomavirus (HPV) genotypes in invasive cervical cancer is crucial to guide the introduction of prophylactic vaccines. We aimed to provide novel and comprehensive data about the worldwide genotype distribution in patients with invasive cervical cancer. Methods Paraffin-embedded samples of histologically confirmed cases of invasive cervical cancer were collected from 38 countries in Europe, North America, central South America, Africa, Asia, and Oceania. Inclusion criteria were a pathological confirmation of a primary invasive cervical cancer of epithelial origin in the tissue sample selected for analysis of HPV DNA, and informa…

OncologyInternational CooperationUterine Cervical NeoplasmsPolymerase Chain ReactionHuman papillomaviruses ; cervical cancer0302 clinical medicineGenotypeMass ScreeningYoung adult10. No inequalityPapillomaviridaeCervical cancerAged 80 and over0303 health sciencesParaffin Embeddingmedicine.diagnostic_testAge FactorsMiddle Aged3. Good healthOncology030220 oncology & carcinogenesisCarcinoma Squamous CellFemaleAdultmedicine.medical_specialtyAdolescentGenotypeHPV vaccinesAdenocarcinoma03 medical and health sciencesCarcinoma AdenosquamousYoung AdultInternal medicinemedicineHumansNeoplasm InvasivenessGenetic TestingPapillomavirus VaccinesGenotyping030304 developmental biologyGenetic testingAgedRetrospective StudiesGynecologybusiness.industryPapillomavirus InfectionsBasic Medical Sciencesmedicine.diseaseCross-Sectional StudiesLogistic ModelsBIOMEDICINE AND HEALTHCAREDNA ViralLinear Array HPV Genotyping TestLinear ModelsCervarixbusinessThe Lancet. Oncology
researchProduct